Single centre, prospective pilot study examining the relevance to screen for Fabry disease in a cohort of patients who have undergone renal transplantation for nephropathy of indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary focal segmental hyalinosis with no established cause.
Exploration whether Fabry disease cases can be identified among patients who are followed at the Montpellier University Hospital after renal transplantation, with indeterminate cause of renal failure or diabetic nephropathy (due to its high frequency) or secondary focal segmental hyalinosis (FSH). At the population level, the identification of cases at the Montpellier centre could then justify to expand this screening to other French centres. The goal is to contribute to adapt current guidelines of renal failure assessment, by systematically including Fabry among the diagnostic tests. Whether all patients with renal failure are concerned, or only those with indeterminate cause, is an important question this study will address.
Study Type
OBSERVATIONAL
Enrollment
592
Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
Uh Montpellier
Montpellier, France
Number of Patients with Positive screen result
The genetic analysis will be performed based on the biochemical results (low enzyme activity, raised lysoGL3)
Time frame: Inclusion visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.